IgA

DRUG2 trials

Sponsors

BIOTEST AG, Biotest AG

Conditions

Non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)Severe community-acquired pneumonia (sCAP)

Phase 3

A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with severe community-acquired pneumonia (sCAP)

Active, not recruitingCTIS2022-501352-28-00

BIOTEST AGSevere community-acquired pneumonia (sCAP)

Start: 2023-06-07Target: 224Updated: 2026-01-12

A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneumonia.

CompletedCTIS2024-513002-60-00

Biotest AGNon-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)

Start: 2022-10-26End: 2025-02-04Target: 198Updated: 2025-01-13